---
title: "Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Budget impact"
description: "Formulary evidence on Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Budget impact. Topics: Summary: price status of rinzimetostat and darolutamide, Summary: comparator prices and costs of care, Summary: eligible population inputs, and Summary: published comparator models. 4 evidence topics quoted from 21 sources."
canonical: "https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary/budget-impact"
published: "2026-11-15T21:45:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Budget impact

<a id="heading-1.1.3"></a>

## 1.1.3 Budget Impact of Rinzimetostat

<a id="topic-1.1.3-1"></a>

### Summary: price status of rinzimetostat and darolutamide

- Rinzimetostat is investigational. ORIC states that it has “not submitted for, or obtained, regulatory approval for any product candidate” and has “no products approved for commercial sale”. The Himalayas-1 phase 3 trial (NCT07723248) of rinzimetostat 400 mg once daily with darolutamide 600 mg twice daily is recruiting, with an actual start date of 3 August 2026 and an estimated primary completion date of March 2028.
- No wholesale acquisition cost, average sales price, brand name, or unit strength of rinzimetostat was identified. ORIC describes post-abiraterone mCRPC as “a $3.5bn total addressable market annually in the US”, and its presentation notes that the figure “assumes current price of ARPIs for illustrative purposes”.
- Darolutamide (Nubeqa, Bayer) is supplied as 300 mg tablets in bottles of 120 tablets. A filing with the California Department of Health Care Access and Information reports a wholesale acquisition cost of $15,100.80 for the 120-tablet bottle (NDC 50419039501), effective 1 January 2026, after an increase of $847.20.
- The labeled darolutamide dose is 600 mg orally twice daily with food, with a concurrent GnRH agonist or antagonist or prior bilateral orchiectomy; for grade 3 or higher or intolerable adverse reactions the dose is withheld or reduced to 300 mg twice daily. Its labeled indications are nmCRPC and mCSPC (alone or in combination with docetaxel); mCRPC is not a labeled indication.
- For Himalayas-1, Bayer provides darolutamide “at no cost for use in the trial in combination with rinzimetostat”, and ORIC retains global development and commercial rights to rinzimetostat.

Source: [ORIC Pharmaceuticals Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526330631/oric-20260630.htm); [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm); [ClinicalTrials.gov NCT07723248](https://clinicaltrials.gov/study/NCT07723248); [Nubeqa prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/212099s016lbl.pdf); [California Department of Health Care Access and Information Prescription Drug Wholesale Acquisition Cost Increases (2026)](https://data.chhs.ca.gov/api/3/action/datastore_search_sql?sql=SELECT%20%22manufacturer_name%22%2C%22ndc%22%2C%22drug_prod_desc%22%2C%22wac_effective_date%22%2C%22wac_increase_amount%22%2C%22wac_after_increase%22%20FROM%20%22dda8a083-bc81-4f6d-b02f-935a2df70328%22%20WHERE%20%22drug_prod_desc%22%20LIKE%20%27Nubeqa%25%27); [ORIC Pharmaceuticals Himalayas-1 initiation release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-announces-initiation-of-himalayas-1-phase-3-trial-in-mcrpc-evaluating-rinzimetostat-in-combination-with-nubeqa-darolutamide-supported-by-clinical-collaboration-with/)

<a id="topic-1.1.3-2"></a>

### Summary: comparator prices and costs of care

- The physician's choice control arm of Himalayas-1 comprises darolutamide 600 mg twice daily, enzalutamide 160 mg once daily, or docetaxel 75 mg/m2 intravenously every 21 days for up to 10 cycles.
- Enzalutamide (Xtandi): the Medicare negotiated price effective 1 January 2027 is $7,004 per 30-day supply, 48% below the calendar year 2024 list price (wholesale acquisition cost) of $13,480.
- Medicare Part B payment limits for 1 October to 31 December 2026, based on second-quarter 2026 ASP data: docetaxel $0.471 per mg; cabazitaxel $231.688 per mg; sipuleucel-T $55,663.131 per infusion; pembrolizumab $62.253 per mg; denosumab $29.856 per mg; zoledronic acid $17.673 per mg. The file lists no payment limit for radium-223 dichloride (“N/A”) and notes $212.84 per microCurie at 100% of AWP and $177.37 per microCurie at 100% of WAC.
- Hospital outpatient payment rates for October 2026 are $180.422 for radium-223 dichloride (A9606, APC 1745) and $266.541 for lutetium Lu 177 vipivotide tetraxetan (A9607, APC 9054).
- Lutetium Lu 177 vipivotide tetraxetan has no ASP-based benchmark. Authors employed by Sanofi, the manufacturer of cabazitaxel, estimated a per-dose cost of $55,522 from the median Medicare Administrative Contractor payment rate, assuming a 200-mCi dose. A published U.S. model used per-cycle costs of $32,062 for lutetium Lu 177 vipivotide tetraxetan, based on the price of 177Lu-DOTATATE as a proxy, and $14,382 for cabazitaxel.
- Costs of care in a cohort of 14,780 men with mCRPC (2019 USD): mean all-cause medical and pharmacy costs per patient per year were $27,468 in the year before mCRPC diagnosis, $148,325 during first-line, $160,118 during second-line, and $165,186 during third-line therapy. In 296 patients progressing from mCSPC to mCRPC, mean all-cause total costs per patient per month increased from $4,424 to $9,717.

Source: [ClinicalTrials.gov NCT07723248](https://clinicaltrials.gov/study/NCT07723248); [CMS negotiated prices fact sheet (2025)](https://www.cms.gov/files/document/fact-sheet-negotiated-prices-ipay-2027.pdf); [CMS Medicare Part B Payment Limit File (2026)](https://www.cms.gov/files/zip/october-2026-medicare-part-b-payment-limit-files-final.zip); [CMS OPPS Addendum B (2026)](https://www.cms.gov/files/zip/October-2026-OPPS-Addendum-B.zip); [Flannery et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13724722/); [Gogebakan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13224915/); [Freedland et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10500004/); [Kaye et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11217864/)

<a id="topic-1.1.3-3"></a>

### Summary: eligible population inputs

- ORIC estimates that “the annual incidence of mCRPC patients previously treated with abiraterone is approximately 17,000” in the U.S., and states that abiraterone has maintained “>50% market share of new prescriptions over the last five years”. These are company-reported figures. No peer-reviewed estimate of the U.S. annual number of men with mCRPC previously treated with abiraterone was identified.
- A U.S. model estimated mCRPC incidence of 36,100 in 2009 and 42,970 in 2020, with 86% of incident mCRPC arising from the nmCRPC clinical state.
- In a real-world cohort of 5,361 patients, 867 (16.2%) had received an ARPI alone and 83 (1.5%) an ARPI and a taxane before mCRPC diagnosis; ARPI-only treatment before mCRPC diagnosis rose from 10.3% in 2018 to 34.8% in 2023, and 76.8% of patients received an ARPI as first-line mCRPC treatment.
- Among 14,780 men newly diagnosed with mCRPC in Medicare fee-for-service claims (January 2014 to June 2019), 78% received at least one line of therapy, 42% at least two, and 20% at least three. Abiraterone accounted for 36% of first-line, 28% of second-line, and 17% of third-line therapy; enzalutamide for 28%, 33%, and 19%; and docetaxel for 16%, 15%, and 24%.

Source: [ORIC Pharmaceuticals RP3D selection release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-reports-selection-of-rinzimetostat-rp3d-in-combination-with-darolutamide-for-himalayas-1-phase-3-global-study-with-dose-optimization-data-supporting-its-potential-best-in-di/); [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm); [Scher et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4603789/); [Swami et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42235146/); [Freedland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11096091/)

<a id="topic-1.1.3-4"></a>

### Summary: published comparator models

- No budget impact model or cost-effectiveness analysis of rinzimetostat was identified.
- A U.S. payer budget impact model of darolutamide in nmCRPC for a hypothetical 1-million-member plan over 5 years estimated approximately 90 incident nmCRPC cases each year and 332 treatment-eligible cases by year 5; introducing darolutamide along with other targeted therapies increased the budget by $158,640 ($0.0132 PMPM) in year 1 and saved $149,240 ($0.0124 PMPM) by year 5.
- A U.S. budget impact analysis of hospitalization costs with darolutamide plus docetaxel in metastatic hormone-sensitive prostate cancer, over a 5-year horizon, reported a cumulative budget impact of -$9.71 per treated member per month.
- A U.S. health care partitioned survival model of lutetium Lu 177 vipivotide tetraxetan versus cabazitaxel (60-month horizon) estimated an incremental cost of $36,258, an incremental gain of 0.10 QALYs, and an ICER of $358,990 per QALY gained. Authors employed by Sanofi state that the model used the price of 177Lu-DOTATATE as a proxy and that “the magnitude of difference is likely greater than reported”.
- A U.S. payer model of third-line cabazitaxel versus a second androgen receptor-targeted agent (18-month horizon) estimated $323,095 (17%) in avoided total costs, 58 fewer hospitalization days, and 2 fewer ICU days.
- A U.S. payer model of genomic test-directed olaparib after a new hormonal agent estimated an ICER of $116,903 per QALY in one scenario and cost savings of $1,980 in the other.

Source: [Appukkuttan et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10394191/); [Morgans et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11365817/); [Gogebakan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13224915/); [Flannery et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13724722/); [Morgans et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9284907/); [Su et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7870786/)

## Related pages
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Terms and abbreviations](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations.md)
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Product information and disease description](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Clinical evidence](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Economic information and modeling report](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: References](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references.md)
